Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 57

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 57
---
. We annualized base salary, target annual bonus and commission for any full-time and part-time employees who commenced work during fiscal year 2024 to reflect a full year, and non-United States employees’ pay was converted to U.S. dollar equivalents using applicable exchange rates as of the determination date.

#### Mirum Pharmaceuticals2025 Proxy Statement47

#### TABLE OF CONTENTS

#### Executive Compensation

#### Pay Versus Performance
The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation Committee view the link between the Company’s performance and named executive officer pay. For further information regarding our compensation philosophy and how we seek to align executive compensation with the Company’s performance, refer to “ Executive Compensation—Compensation Discussion and Analysis. ”

Required Tabular Disclosure of Pay Versus Performance

The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” (or “ CAP ”) is required by the SEC’s rules and, as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation described in the section titled “Executive Compensation”.

|      |     | Summary Compensation Table Total for our Principal Executive Officer 
 (“PEO”)(1)(2)                                                        |           |    | Compensation Actually Paid to PEO(1)(3) |            |    | Average Summary Compensation Table Total for Non-PEO Named Executive Officers (“NEOs”)(1)(2) |           |    | Average Compensation Actually Paid to Non-PEO NEOs(1)(3) |           |    | Value of Initial Fixed $100 Investment Based On: |     |        |     |       | Net Loss          
 (in thousands)(5) |          |    | Net Product Sales (in thousands)(6) |         |    |
|      |     | Total Stockholder Return (“TSR”)(4)                                  |           |    | Peer Group Total Shareholder Return(4)  |            |    |                                                                                              |           |    |                                                          |           |    |                                                  |     |        |     |       |                   |          |    |                                     |         |    |
| Year |     |                                                                      |           | -$ |                                         |            | -$ |                                                                                              |           |